Posted On: Wednesday, June 4th, 2014
New and Noteworthy Application to Health Canada submitted for approval of AbbVie anti-hep C drug combination AbbVie has filed a new drug submission to Health Canada for approval of a combination of drugs for adults with genotype 1 hepatitis C virus. The treatment consists of: ombitasvir and ABT-450 boosted with ritonavir as a fixed dose,… Read more »
Posted On: Wednesday, May 28th, 2014
Posted On: Wednesday, May 28th, 2014
New and Noteworthy TreatmentUpdate 202: Hepatitis C Virus The latest issue of TreatmentUpdate contains in-depth information about Hep C treatments that have recently been approved by Health Canada, including sofosbuvir (Sovaldi) and simeprevir (Galexos), and new Hep C treatments in development. More surprises ahead for hepatitis C therapy Abbvie’s potent combination Simeprevir – potential drug… Read more »
Posted On: Tuesday, May 13th, 2014
New and Noteworthy Staying Safe Intervention reduces risk for Hep C and HIV in people who inject drugs An evaluation of an intervention designed to prevent the transmission of Hep C and HIV among people who inject drugs has shown decreases in behaviours considered a risk for contracting Hep C and HIV. This strengths-based intervention… Read more »
Posted On: Wednesday, May 7th, 2014
New and Noteworthy World Health Organization releases global guidelines for Hep C treatment The World Health Organization (WHO) has released global guidelines for the screening, care and treatment of people with hepatitis C. The guidelines recommend: Sofosbuvir (Sovaldi) and ribavirin with genotype 1,2,3 or 4 virus, with or without peg-interferon, depending on the genotype, or;… Read more »
Posted On: Wednesday, May 7th, 2014
Hepatitis C virus (HCV) infects the liver and injures this organ. If HCV is left untreated, over time this virus continues to injure the liver, causing inflammation and the replacement of healthy, functional liver tissue with scar tissue. In chronic HCV infection, the liver gradually becomes dysfunctional, complications occur and the risk of developing liver… Read more »
Posted On: Wednesday, April 16th, 2014
As provided by the Public Health Agency of Canada (PHAC), Western Region, here is a list of all PHAC-funded HIV and Hepatitis C projects in British Columbia. The time frame for these projects is April 1st, 2014 to March 31st, 2017 are available.
Posted On: Wednesday, April 16th, 2014
New and Noteworthy In this issue of HepCinfo Update, we cover selected results from four clinical trials of Hep C medication combinations presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014). These trials are noteworthy for a number of reasons: The cure rates in all of these trials are very high (85-99%)…. Read more »
Posted On: Thursday, April 10th, 2014
Posted On: Thursday, April 10th, 2014
Hepatitis C virus (HCV) can infect the liver, causing inflammation that injures this organ. If HCV is left untreated, injury can spread throughout the liver and this organ consequently becomes increasingly dysfunctional. As a result, the eventual appearance of serious symptoms related to liver damage occurs and a person’s quality of life degrades. HCV infection… Read more »
Posted On: Wednesday, April 2nd, 2014
Under the Federal Initiative to Address HIV/AIDS in Canada and the Hepatitis C Prevention, Support and Research Program, the Agency currently manages separate funding programs to support the community response to HIV and hepatitis C. The projects under these programs are in the process of being extended for three years, from April 1, 2014 –… Read more »
Posted On: Wednesday, April 2nd, 2014
6 week treatment cures almost all “hard to treat” participants A six-week treatment of sofosbuvir (Sovaldi), ledipasvir and a third drug cured a majority of people with genotype 1 Hep C virus who had never been treated before, according to research presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) in Boston…. Read more »
